Indenebart Biosimilar Monoclonal Antibody (α-Synuclein) for Research

Cat No.: GMP-Bios-INN-1236

Anti-SNCA/PARK1/PARK4 therapeutic antibody (Pre-made Indenebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Indenebart (development codes MEDI-1341/TAK-341) is a humanized monoclonal antibody targeting alpha-synuclein (SNCA). It is developed by AstraZeneca/MedImmune and Takeda for multiple system atrophy and Parkinson's disease. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1236-1mg 1mg 3090
GMP-Bios-INN-1236-10mg 10mg
GMP-Bios-INN-1236-100mg 100mg
GMP-Bios-INN-1236-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Indenebart biosimilar, Whole mAb, Anti-SNCA/PARK1/PARK4 Antibody: Anti-Alpha Synuclein/SNCA/Alpha-synuclein/Non-A beta component of AD amyloid therapeutic antibody
INN Name Indenebart
Target SNCA/PARK1/PARK4
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies MedImmune;AstraZeneca;Takeda
Conditions Approved na
Conditions Active Multiple system atrophy;Parkinson's disease
Conditions Discontinued na
Production na
Development Tech na